EFSA EUSR-AMR Workflow and Criteria for ESBL/AmpC/Carbapenemase -Phenotypes



Beatriz Guerra EURL-AR Workshop – 15 April 2016

www.efsa.europa.eu





- Background documents
- Workflows (WFs)
 - Workflow ESBL and AMPc
 - Workflow NON ESBL
 - Workflow CARBAPENEMASE
- Criteria
- Validation
- Conclussions





- Background documents
- Workflows (WFs)
 - Workflow ESBL and AMPc
 - Workflow NON ESBL
 - Workflow CARBAPENEMASE
- Criteria
- Validation
- Conclussions





BACKGROUND USED TO SET CRITERIA

EUCAST EUCAST ON ANTIMICROBIAL SUSCEPTIBILITY TES

European Society of Clinical Microbiology and Infectious Disc

COMMISSION IMPLEMENTING DECISION

of 12 November 2013

on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria

(notified under document C(2013) 7145)

(Text with EEA relevance)

(2013/652/EU)

Table 4

Panel of antimicrobial substances, EUCAST epidemiological cut-off values (ECOFFs) and clinical resistance breakpoints and concentrations ranges to be used for testing only *Salunonella* spp. and indicator commensal *E. coli* isolates resistant to ceforatime or cefrazidime or meropenem — (Second panel)

EUCAST guidelines for detection of resistance
mechanisms and specific resistances of clinical
and/or epidemiological importance

Version 1.0 December 2013

EFSA Journal 2012;10(6):2742

SCIENTIFIC REPORT OF EFSA

Technical specifications on the harmonised monitoring and reporting of antimicrobial resistance in *Salmonella*, *Campylobacter* and indicator *Escherichia coli* and *Enterococcus* spp. bacteria transmitted through food¹

European Food Safety Authority^{2, 3}

Antimicrobial	Species	Interpretative thresholds of AMR (mg/L)		Range of concentrations
		ECOFF (*)	Clinical breakpoint (*)	(No of wells in brackets)
Cefoxitin	Salmonella	> 8	NA	0,5-64 (8)
	E. coli	> 8	NA	
Cefepime	Salmonella	NA	NA	0,06-32 (10)
	E. coli	> 0,125	> 4	
Cefotaxime + clavulanic acid (*)	Salmonella	NA (**)	NA (**)	0,06-64 (11)
	E. coli	NA (**)	NA (**)	
Ceftazidime + clavulanic acid (*)	Salmo <mark>ne</mark> lla	NA (**)	NA (**)	0,125-128 (11)
	E. coli	NA (**)	NA (**)	
Meropenem	Salmonella	> 0,125	> 8	0,03-16 (10)
	F. coli	> 0,125	> 8	
Temocillin	Salmonella	NA	NA	0,5-64 (8)
	E. coli	NA	NA	
Imipenem	Salmo <mark>nell</mark> a	> 1	> 8	0,12-16 (8)
	E. coli	> 0,5	> 8	
Ertapenem	Salmonella	> 0,06	> 1	0,015-2 (8)
	E. coli	> 0,06	> 1	
Cefotaxime	Salmonella	> 0.5	> 2	0,25-64 (9)
	E. coli	> 0,25	> 2	
Ceftazidime	Salmo <mark>nel</mark> la	> 2	> 4	0,25-128 (10)
	E. coli	> 0,5	> 4	







- Background documents
- Workflows (WFs)
 - Workflow ESBL and AMPc
 - Workflow NON ESBL
 - Workflow CARBAPENEMASE



- Validation
- Conclussions





WORKFLOW (WF) ESBL AND AMPC

ESBL/AmpC/ESBL+AmpC Phenotypes







WORKFLOW NON ESBL

Non ESBL Phenotypes







WORKFLOW CARBAPENEMASE

Carbapenemase-Phenotype



*Confirmation by molecular/biochemical tests needed. **i.e. if SYN CLAV, suggest +ESBL * Some CP-producers could be found here. Confirmation by molecular/biochemical tests needed.



SF	CRITERIA					
	ESBL-Phenotype - FOT or TAZ > 1 mg/L AND - MERO ≤ 0.12 mg/L AND - FOX ≤ 8 mg/L AND -SYN FOT/CLV and/or TAZ/CLV	AmpC-Phenotype - FOT or TAZ > 1 mg/L AND - MERO ≤ 0.12 mg/L AND - FOX > 8 mg/L AND - No SYN FOT/CLV nor TAZ/CLV - (Not excluded presence of ESBLs)				
	ESBL + AmpC-	Carbapenemase-				
COLUMN TO A	Phenotype	Phenotype	Susceptible			
	-FOT or TAZ > 1 mg/L AND -MERO \leq 0.12 mg/L AND - FOX >8 mg/L AND - SYN FOT/CLV and/or TAZ/CLV	 MEROM > 0.12 mg/L Needs confirmation (Not excluded presence of ESBLs or AmpC) 	FOT-TAZ-FOX-MEM ≤ ECOFF			
	Other phenotypes					
N M V	 If FOT or TAZ > 1 mg/ml AND MEM ≤ 0.12 mg/L AND FOX ≤ 8 mg/L AND NO SYN FOT/CLV nor TAZ/CLV Not excluded CPs (consult EURL) 	 3) If FOT and/or TAZ ≤ 1 mg/L - MERO ≤ 0.12 mg/L - FOX > 8 mg/L. -*cAmpCs could be included here 	2			
- 	2) If FOT and/or TAZ \leq 1 mg/L AND > ECOF - MERO \leq 0.12 mg/L - FOX \leq 8 mg/L	 4) If MERO ≤ 0.12 mg/L BUT F AND - ETP > ECOFF AND/OR - IMI > ECOFF - Not excluded CPs, needs confirmed to the excluded CPs. 	nation (consult EURL)			

- IMI > ECOFF
- Not excluded CPs, needs confirmation (consult EURL)

5) Any other combinations not described in previous boxes (contact EURL)

9





- Background documents
- Workflows (WFs)
 - Workflow ESBL and AMPc
 - Workflow NON ESBL
 - Workflow CARBAPENEMASE

Criteria

Validation

Conclussions





VALIDATION

- MSs provided genotypic data: BE, SE, ES, CZ, IT
- Comparisson of results with MSs that provided both Panel 2 phenotypical data and genetic data:
 - All excepting 6 out of 151 isolates correctly classified

Differences for classification:

- "Presumptive ESBL + AmpC-producers" with reported low MIC values for FOX:
 - Could be related, at least in *E. coli*, with putative expression of intrinsic AmpC genes (not reported to us).
 - Could be related to reporting 1 step MIC over the ECOFF
- 1 isolate no synergy reported and no FOX, but SHV-positive
 - Wrong reporting? Other mechanisms not detected?

To analyse results from last PTs applying the criteria (to be done)





CONCLUSSIONS

- As we only have phenotypic data...
- ...and different combinations of genes exist
- ...and "wrong" reporting is possible
- …and "wrong" interpretation is possible
- …and strange results can appear
- Overseing mechanisms /missclassification can happens but most of the results can be inferred in the right way!!!
- For CPs, molecular/biochemical confirmation is needed. In other cases, is recommended.
- In case of problems when interpreting results, please contact EURL-AR or EFSA





THANK YOU FOR YOUR ATTENTION !

Thanks to: EFSA AMR Team (P-A, Anca, Ernesto) EURL-AR Team (Lina, Valeria) Other experts: H. Hasman, S. Granier, C. Teale MSs, specially for providing genetic data

2014 EU Summary Report on AMR

<u>www.efsa.europa.eu</u>

Dr. Beatriz Guerra Román

Unit of Biological Hazards and Contaminants (BIOCONTAM) Risk Assessment and Scientific Assistance Directorate

European Food Safety Authority (EFSA) Via Carlo Magno 1A 43126 Parma, Italy Tel: +39 0521 036 459 Fax: +39 0521 036 0459 Email: <u>beatriz.guerra@efsa.europa.eu</u> Website: <u>www.efsa.europa.eu</u>

